CVE:SVA

Sernova - SVA Stock Forecast, Price & News

C$1.57

+0.09 (+6.08%)

(As of 06/1/2022)

Add

Compare

Today's Range: C$1.46
▼
C$1.57
50-Day Range: C$1.57
▼
C$1.57
52-Week Range: C$1.16
▼
C$2.22

Volume: 121,355 shs
Average Volume: 288,358 shs
Market Capitalization: C$432.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$6.00

Sernova MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 282.2% Upside
C$6.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
C$64,500 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Sernova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$6.00, Sernova has a forecasted upside of 282.2% from its current price of C$1.57.
Amount of Analyst Coverage
Sernova has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SVA.

0.0

Dividend Strength

Dividend Yield
Sernova does not currently pay a dividend.
Dividend Growth
Sernova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SVA.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Sernova this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for SVA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Sernova to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sernova insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$64,500.00 in company stock and sold C$0.00 in company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sernova has a P/B Ratio of 15.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sernova (CVE:SVA) Stock

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter.

SVA Stock News Headlines

August 11, 2022 | streetinsider.com

Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates - StreetInsider.com

August 8, 2022 | globenewswire.com

Type 1 Diabetes Pipeline Landscape Analysis of 80+ Companies by DelveInsight - GlobeNewswire

July 6, 2022 | nasdaq.com

CANADA STOCKS-TSX futures down as commodities fall on recession worries - Nasdaq

July 5, 2022 | baystreet.ca

Futures Demur Tuesday with Oil, Metal Price - Baystreet.ca

July 5, 2022 | baystreet.ca

TSX Loses Much of Monday’s Gains - Baystreet.ca

June 15, 2022 | globenewswire.com

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June - GlobeNewswire

June 15, 2022 | finance.yahoo.com

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June

June 10, 2022 | ca.finance.yahoo.com

Sernova Corp. (SVA.TO)

June 6, 2022 | globenewswire.com

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022 - GlobeNewswire

June 2, 2022 | finance.yahoo.com

Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development - Yahoo Finance

June 2, 2022 | finance.yahoo.com

Altos Labs Announces Sponsored Research Agreement with Kyoto University's CiRA to Foster Cellular Rejuvenation Programming Research - Yahoo Finance

June 2, 2022 | finance.yahoo.com

TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference - Yahoo Finance

May 17, 2022 | globenewswire.com

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes - GlobeNewswire

May 17, 2022 | finance.yahoo.com

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes - Yahoo Finance

May 17, 2022 | finance.yahoo.com

Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes - Yahoo Finance

March 24, 2022 | businesswire.com

2022 Global Conformal Coatings Technology Growth Opportunities - ResearchAndMarkets.com - Business Wire

January 10, 2022 | ca.finance.yahoo.com

IIROC Trading Halt - SVA

December 27, 2021 | finance.yahoo.com

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

November 16, 2021 | uk.finance.yahoo.com

Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

July 28, 2021 | uk.finance.yahoo.com

Sernova Corp. (SVA.V)

October 16, 2020 | ca.finance.yahoo.com

Sernova Corp. Registered Shares (PSH.SG)

October 13, 2020 | au.finance.yahoo.com

SERNOVA CORP. (PSH.MU)

August 17, 2020 | ca.finance.yahoo.com

Sernova Corp. (PSH.F)

August 1, 2020 | au.finance.yahoo.com

SERNOVA CORP. (PSH.BE)

May 29, 2020 | www.businesswire.com

AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: CVE
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: CVE:SVA
CUSIP: N/A
CIK: N/A
Web: www.sernova.com
Phone: +1-519-8585184
Fax: N/A
Employees: 1,959
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$6.00
High Stock Price Forecast: C$6.00
Low Stock Price Forecast: C$6.00
Forecasted Upside/Downside: +282.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1.34
Current Ratio: 13.76
Quick Ratio: 13.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.10 per share
Price / Cash Flow: 15.10
Book Value: C$0.10 per share
Price / Book: 15.10

Miscellaneous

Outstanding Shares: 275,525,000
Free Float: N/A
Market Cap: C$432.57 million
Optionable: Optionable
Beta: N/A

Key Competitors

View All Competitors

Insiders & Institutions

Frank Holler
Bought 50,000 shares on 6/17/2022
Total: C$64,500.00 ($1.29/share)

View All Insider Transactions
View All Institutional Transactions

SVA Stock - Frequently Asked Questions

Should I buy or sell Sernova stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVA shares.
View SVA analyst ratings or view top-rated stocks.
What is Sernova's stock price forecast for 2022?: 2 equities research analysts have issued twelve-month price targets for Sernova's stock. Their SVA share price forecasts range from C$6.00 to C$6.00. On average, they predict the company's stock price to reach C$6.00 in the next twelve months. This suggests a possible upside of 282.2% from the stock's current price.
View analysts price targets for SVA or view top-rated stocks among Wall Street analysts.
How have SVA shares performed in 2022?: Sernova's stock was trading at C$1.82 at the beginning of the year. Since then, SVA stock has decreased by 13.7% and is now trading at C$1.57.
View the best growth stocks for 2022 here.
What other stocks do shareholders of Sernova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sernova investors own include Gilead Sciences (GILD), New Residential Investment (NRZ), SMART Global (SGH), Big Lots (BIG), Bernstein U.S. Research Fund (BERN), Bank of America (BAC), Alibaba Group (BABA), AstraZeneca (AZN), Liberty All-Star Growth Fund (ASG) and Ares Capital (ARCC).

What is Sernova's stock symbol?: Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."
How do I buy shares of Sernova?: Shares of SVA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Sernova's stock price today?: One share of SVA stock can currently be purchased for approximately C$1.57.
How much money does Sernova make?: Sernova (CVE:SVA) has a market capitalization of C$432.57 million.
How many employees does Sernova have?: The company employs 1,959 workers across the globe.
How can I contact Sernova?: Sernova's mailing address is 700 Collip Cir Suite 114, LONDON, ON N6G 4X8, Canada. The official website for the company is www.sernova.com. The company can be reached via phone at +1-519-8585184.

This page (CVE:SVA) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Sernova - SVA Stock Forecast, Price & News

Sernova MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sernova (CVE:SVA) Stock

SVA Stock News Headlines

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Competitors

Insiders & Institutions

SVA Stock - Frequently Asked Questions

Should I buy or sell Sernova stock right now?

What is Sernova's stock price forecast for 2022?

How have SVA shares performed in 2022?

What other stocks do shareholders of Sernova own?

What is Sernova's stock symbol?

How do I buy shares of Sernova?

What is Sernova's stock price today?

How much money does Sernova make?

How many employees does Sernova have?

How can I contact Sernova?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™